Nature Neuroscience · 2023 · 104 citations · 87 references
Life SciencesNeurologyNeuroscienceDementiaMolecular NeuroscienceNeurodegenerationAlzheimer DiseaseNeurodegenerative DiseasesNeurodegenerative DisordersNeuroinflammationNeuroprotectionTau PathologyAlzheimer Disease Tau PathologyApoe GeneticsLate Onset Alzheimer DiseasePsen1 MutationsSingle-nucleus Rna SequencingSingle-nucleus SequencingTau HyperphosphorylationTauopathy Models
Apolipoprotein E4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (LOAD), leading to earlier age of clinical onset and exacerbating pathologies. There is a critical need to identify protective targets. Recently, a rare APOE variant, APOE3-R136S (Christchurch), was found to protect against early-onset AD in a PSEN1-E280A carrier. In this study, we sought to determine if the R136S mutation also protects against APOE4-driven effects in LOAD. We generated tauopathy mouse and human iPSC-derived neuron models carrying human APOE4 with the homozygous or heterozygous R136S mutation. We found that the homozygous R136S mutation rescued APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. The heterozygous R136S mutation partially protected against APOE4-driven neurodegeneration and neuroinflammation but not Tau pathology. Single-nucleus RNA sequencing revealed that the APOE4-R136S mutation increased disease-protective and diminished disease-associated cell populations in a gene dose-dependent manner. Thus, the APOE-R136S mutation protects against APOE4-driven AD pathologies, providing a target for therapeutic development against AD.
87
Fitting Linear Mixed-Effects Models Using <b>lme4</b>
Douglas M. Bates, Martin Mächler, Benjamin M. Bolker et al. · Journal of Statistical Software · 2015 · 85.6K citations · Full text
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin, Ignacio Arganda‐Carreras, Erwin Frise et al. · Nature Methods · 2012 · 70.9K citations